# IDP-002

Source: https://onco.cc/drugs/idp-002/  
OnCo record `idp-002` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IDP-002 is an experimental bispecific PD-1 antagonist from InduPro Therapeutics, in preclinical development for cancer.

## Summary

IDP-002 is a bispecific PD-1 antagonist from InduPro Therapeutics. A bispecific PD-1 antagonist that binds PD-1 together with an undisclosed T-cell antigen for cooperative binding; the company says it does not depend on VEGF. Its furthest stage is preclinical development, for cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Listed under Immuno-Oncology; pipeline chart bar in the lead-optimisation column (HTML data-width 48); no registered trial found. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: IDP-002
- Modality: Bispecific PD-1 antagonist
- Mechanism: A bispecific PD-1 antagonist that binds PD-1 together with an undisclosed T-cell antigen for cooperative binding; the company says it does not depend on VEGF.

## Sources

- InduPro Therapeutics: induprotx.com: https://www.induprotx.com/pipeline

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- companies: [InduPro Therapeutics](https://onco.cc/companies/indupro-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/idp-002.json